[Bone marrow scintigraphy. Principles, clinical results and indications]

Area of Science:

• Nuclear medicine
• Radiopharmacology
• Oncology imaging

Background:

• Bone marrow scintigraphy is crucial for evaluating hematopoietic and reticuloendothelial systems.
• Advancements in radiopharmaceuticals enable imaging of granulopoietic activity.
• Accurate staging of cancers and lymphomas relies on comprehensive bone marrow assessment.

Purpose of the Study:

• To introduce and compare radiopharmaceuticals for scintigraphy of erythropoietic, reticuloendothelial, and granulopoietic bone marrow.
• To present clinical results and applications of bone marrow scanning.
• To identify optimal radiopharmaceuticals for specific oncological indications.

Main Methods:

• Review of anatomical and physiological principles relevant to bone marrow imaging.
• Introduction and comparison of various radiopharmaceuticals for bone marrow scintigraphy.
• Analysis of clinical data from bone marrow scans in cancer patients.

Main Results:

• Radiopharmaceuticals for erythropoietic, reticuloendothelial, and granulopoietic bone marrow imaging are detailed.
• Clinical results demonstrate the utility of bone marrow scans for staging various malignancies.
• Technetium-99m labelled monoclonal anti-NCA-95 antibodies show promise as a preferred agent.

Conclusions:

• Bone marrow scintigraphy is a valuable tool in oncology.
• 99mTc-labelled monoclonal anti-NCA-95 antibodies are a promising radiopharmaceutical for staging lymphomas and other cancers.
• Further evaluation of granulopoietic imaging agents is warranted.